Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-02

AUTHORS

Jinshan Shen, Robert Townsend, Xiaoli You, Yun Shen, Ping Zhan, Zexun Zhou, Dong Geng, Dianna Wu, Nadia McGirr, Kathleen Soucek, Elizabeth Proszynski, Janice Pursley, Eric Masson

ABSTRACT

BACKGROUND AND OBJECTIVES: Belatacept is a first-in-class, selective co-stimulation blocker recently approved for the prophylaxis of organ rejection in adult kidney transplant recipients. The objective of this study was to report the pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept. METHODS: The pharmacokinetics, pharmacodynamics (CD86 receptor occupancy), and immunogenicity of belatacept were studied in de novo adult kidney transplant recipients in phase II and III clinical studies. RESULTS: Following multiple doses of 5 or 10 mg/kg, the geometric mean (percentage coefficient of variation) maximum serum concentration and area under the serum concentration-time curve over one dosing interval of belatacept were 136 (20%) and 238 (27%) μg/mL, and 13,587 (27%) and 21,241 (35%) μg·h/mL, respectively. The median belatacept elimination half-life was 8-9 days. Belatacept exhibited concentration-dependent binding to CD86 receptors. The pre-dose CD86 receptor occupancy by belatacept decreased from 94 to 65% between day 5 and 1 year post-transplant, with corresponding pre-dose trough serum concentrations of belatacept decreasing from ~35 to 4 μg/mL during this period. The cumulative incidence of developing anti-belatacept antibodies was 5.3% up to 3 years post-transplant and had no impact on belatacept exposure. CONCLUSIONS: Belatacept in adult kidney transplant demonstrated linear pharmacokinetics with low variability, concentration-dependent pharmacodynamics, and a low incidence of anti-drug antibodies. More... »

PAGES

117-126

References to SciGraph publications

  • 2012-08. Time‐Varying Belatacept Exposure and Its Relationship to Efficacy/Safety Responses in Kidney‐Transplant Recipients in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 2011-02. Oral Session II‐B (OII‐B) in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 2010-05. CYP-Mediated Therapeutic Protein-Drug Interactions in CLINICAL PHARMACOKINETICS
  • 2009-09. Immunotherapy in Elderly Transplant Recipients in DRUGS & AGING
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s40261-013-0153-2

    DOI

    http://dx.doi.org/10.1007/s40261-013-0153-2

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1050298806

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/24217983


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Abatacept", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibodies", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Area Under Curve", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "B7-2 Antigen", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Clinical Trials, Phase II as Topic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Clinical Trials, Phase III as Topic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Dose-Response Relationship, Drug", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Half-Life", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunoconjugates", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunosuppressive Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Kidney Transplantation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Time Factors", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Shen", 
            "givenName": "Jinshan", 
            "id": "sg:person.0646360451.54", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646360451.54"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Townsend", 
            "givenName": "Robert", 
            "id": "sg:person.01166761064.07", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166761064.07"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "You", 
            "givenName": "Xiaoli", 
            "id": "sg:person.01336302136.32", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336302136.32"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Shen", 
            "givenName": "Yun", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Zhan", 
            "givenName": "Ping", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Zhou", 
            "givenName": "Zexun", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Geng", 
            "givenName": "Dong", 
            "id": "sg:person.0775237636.64", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775237636.64"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Wu", 
            "givenName": "Dianna", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "McGirr", 
            "givenName": "Nadia", 
            "id": "sg:person.01111466236.19", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111466236.19"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Soucek", 
            "givenName": "Kathleen", 
            "id": "sg:person.01157601436.77", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157601436.77"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Proszynski", 
            "givenName": "Elizabeth", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Pursley", 
            "givenName": "Janice", 
            "id": "sg:person.0630643206.07", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630643206.07"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Masson", 
            "givenName": "Eric", 
            "id": "sg:person.014363567577.38", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014363567577.38"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "https://doi.org/10.1111/j.1600-6143.2005.00749.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005387107"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1111/j.1600-6143.2005.00749.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005387107"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1111/j.1600-6143.2005.00749.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005387107"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1111/j.1600-6143.2004.00332.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008106653"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/tp.0b013e3182007b95", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009438606"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/tp.0b013e3182007b95", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009438606"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/tp.0b013e3182007b95", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009438606"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1681/asn.2009111109", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012075613"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1681/asn.2009111109", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012075613"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/tp.0b013e3181ff87cd", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012888147"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/tp.0b013e3181ff87cd", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012888147"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/tp.0b013e3181ff87cd", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012888147"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1371/journal.pone.0026459", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016973491"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/tp.0b013e31819b5a58", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017865661"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/tp.0b013e31819b5a58", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017865661"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/tp.0b013e31819b5a58", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017865661"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/clpt.2012.84", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020898645", 
              "https://doi.org/10.1038/clpt.2012.84"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/11319980-000000000-00000", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022781285", 
              "https://doi.org/10.2165/11319980-000000000-00000"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/11319980-000000000-00000", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022781285", 
              "https://doi.org/10.2165/11319980-000000000-00000"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1111/j.1600-6143.2010.03016.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023223598"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1111/j.1600-6143.2010.03016.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023223598"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/11316480-000000000-00000", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025688462", 
              "https://doi.org/10.2165/11316480-000000000-00000"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/11316480-000000000-00000", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025688462", 
              "https://doi.org/10.2165/11316480-000000000-00000"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/clpt.2010.331", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026754692", 
              "https://doi.org/10.1038/clpt.2010.331"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1177/0091270007306958", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031261826"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.2215/cjn.03791106", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031418032"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1111/j.1600-6143.2010.03338.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035491415"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1111/j.1600-6143.2010.03338.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035491415"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejmra033540", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041854653"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1111/j.1600-6143.2009.03005.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051343043"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1111/j.1600-6143.2009.03005.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051343043"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejmoa050085", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052307919"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejmoa050085", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052307919"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.4155/bio.10.54", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052956253"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.4155/bio.12.79", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1053687013"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2014-02", 
        "datePublishedReg": "2014-02-01", 
        "description": "BACKGROUND AND OBJECTIVES: Belatacept is a first-in-class, selective co-stimulation blocker recently approved for the prophylaxis of organ rejection in adult kidney transplant recipients. The objective of this study was to report the pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept.\nMETHODS: The pharmacokinetics, pharmacodynamics (CD86 receptor occupancy), and immunogenicity of belatacept were studied in de novo adult kidney transplant recipients in phase II and III clinical studies.\nRESULTS: Following multiple doses of 5 or 10 mg/kg, the geometric mean (percentage coefficient of variation) maximum serum concentration and area under the serum concentration-time curve over one dosing interval of belatacept were 136 (20%) and 238 (27%) \u03bcg/mL, and 13,587 (27%) and 21,241 (35%) \u03bcg\u00b7h/mL, respectively. The median belatacept elimination half-life was 8-9 days. Belatacept exhibited concentration-dependent binding to CD86 receptors. The pre-dose CD86 receptor occupancy by belatacept decreased from 94 to 65% between day 5 and 1 year post-transplant, with corresponding pre-dose trough serum concentrations of belatacept decreasing from ~35 to 4 \u03bcg/mL during this period. The cumulative incidence of developing anti-belatacept antibodies was 5.3% up to 3 years post-transplant and had no impact on belatacept exposure.\nCONCLUSIONS: Belatacept in adult kidney transplant demonstrated linear pharmacokinetics with low variability, concentration-dependent pharmacodynamics, and a low incidence of anti-drug antibodies.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1007/s40261-013-0153-2", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1100199", 
            "issn": [
              "1173-2563", 
              "1179-1918"
            ], 
            "name": "Clinical Drug Investigation", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "2", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "34"
          }
        ], 
        "name": "Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients", 
        "pagination": "117-126", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "ef9bc3a1091751c77f1ed53a199e732255a92367ec320256281417411c56aa02"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "24217983"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "9504817"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s40261-013-0153-2"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1050298806"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s40261-013-0153-2", 
          "https://app.dimensions.ai/details/publication/pub.1050298806"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-11T09:57", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89807_00000002.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "http://link.springer.com/10.1007%2Fs40261-013-0153-2"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40261-013-0153-2'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40261-013-0153-2'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40261-013-0153-2'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40261-013-0153-2'


     

    This table displays all metadata directly associated to this object as RDF triples.

    268 TRIPLES      21 PREDICATES      63 URIs      35 LITERALS      23 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s40261-013-0153-2 schema:about N0371d7201dc64e3aba2f141b6313e441
    2 N17281161b3ea411698484893e9e53fa4
    3 N43a071330379414dac6deb1bc6eaa021
    4 N51bb90272f2a4e419173629d937c8e28
    5 N63db32fd56434c80a85895f256e71868
    6 N92594c8c03d9455cb74cfb6828d52b13
    7 N957a909c3e48463e9c74e0b7b2734997
    8 N9d1aec74ad924109a8f28b837abbb778
    9 Nb9467871d97841769433b7de866dca49
    10 Nce7c8c54400b479781378e65cd9ddc2d
    11 Nd05ad56666e0456c8bb1cc93424d1457
    12 Nd137d44b78b44dedaaf8135644b139e0
    13 Ne4200569f18b49b89f2f3ecb3a6c615f
    14 Ne4d5082815cd4b38a6c0053639dafa1e
    15 anzsrc-for:11
    16 anzsrc-for:1103
    17 schema:author N17bd77daadac4de48ff4c8a134c65653
    18 schema:citation sg:pub.10.1038/clpt.2010.331
    19 sg:pub.10.1038/clpt.2012.84
    20 sg:pub.10.2165/11316480-000000000-00000
    21 sg:pub.10.2165/11319980-000000000-00000
    22 https://doi.org/10.1056/nejmoa050085
    23 https://doi.org/10.1056/nejmra033540
    24 https://doi.org/10.1097/tp.0b013e31819b5a58
    25 https://doi.org/10.1097/tp.0b013e3181ff87cd
    26 https://doi.org/10.1097/tp.0b013e3182007b95
    27 https://doi.org/10.1111/j.1600-6143.2004.00332.x
    28 https://doi.org/10.1111/j.1600-6143.2005.00749.x
    29 https://doi.org/10.1111/j.1600-6143.2009.03005.x
    30 https://doi.org/10.1111/j.1600-6143.2010.03016.x
    31 https://doi.org/10.1111/j.1600-6143.2010.03338.x
    32 https://doi.org/10.1177/0091270007306958
    33 https://doi.org/10.1371/journal.pone.0026459
    34 https://doi.org/10.1681/asn.2009111109
    35 https://doi.org/10.2215/cjn.03791106
    36 https://doi.org/10.4155/bio.10.54
    37 https://doi.org/10.4155/bio.12.79
    38 schema:datePublished 2014-02
    39 schema:datePublishedReg 2014-02-01
    40 schema:description BACKGROUND AND OBJECTIVES: Belatacept is a first-in-class, selective co-stimulation blocker recently approved for the prophylaxis of organ rejection in adult kidney transplant recipients. The objective of this study was to report the pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept. METHODS: The pharmacokinetics, pharmacodynamics (CD86 receptor occupancy), and immunogenicity of belatacept were studied in de novo adult kidney transplant recipients in phase II and III clinical studies. RESULTS: Following multiple doses of 5 or 10 mg/kg, the geometric mean (percentage coefficient of variation) maximum serum concentration and area under the serum concentration-time curve over one dosing interval of belatacept were 136 (20%) and 238 (27%) μg/mL, and 13,587 (27%) and 21,241 (35%) μg·h/mL, respectively. The median belatacept elimination half-life was 8-9 days. Belatacept exhibited concentration-dependent binding to CD86 receptors. The pre-dose CD86 receptor occupancy by belatacept decreased from 94 to 65% between day 5 and 1 year post-transplant, with corresponding pre-dose trough serum concentrations of belatacept decreasing from ~35 to 4 μg/mL during this period. The cumulative incidence of developing anti-belatacept antibodies was 5.3% up to 3 years post-transplant and had no impact on belatacept exposure. CONCLUSIONS: Belatacept in adult kidney transplant demonstrated linear pharmacokinetics with low variability, concentration-dependent pharmacodynamics, and a low incidence of anti-drug antibodies.
    41 schema:genre research_article
    42 schema:inLanguage en
    43 schema:isAccessibleForFree true
    44 schema:isPartOf N279339dfb7b54e1da28521ef6ffa79f5
    45 N28528d82a61949db9f99e1bac0785a63
    46 sg:journal.1100199
    47 schema:name Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients
    48 schema:pagination 117-126
    49 schema:productId N33fabb5798f14548b002bd3d47a515c9
    50 N9b2b2080408e435da502e48dbd469dee
    51 Nb7e2ac01c61548c485e00ace7756caa8
    52 Nba28c3ed7ded4d97a077d29032a15dfc
    53 Nfddc6d8555194374b13de69132ae793b
    54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050298806
    55 https://doi.org/10.1007/s40261-013-0153-2
    56 schema:sdDatePublished 2019-04-11T09:57
    57 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    58 schema:sdPublisher N10cf43f66b054561bfd3ff3675205855
    59 schema:url http://link.springer.com/10.1007%2Fs40261-013-0153-2
    60 sgo:license sg:explorer/license/
    61 sgo:sdDataset articles
    62 rdf:type schema:ScholarlyArticle
    63 N0371d7201dc64e3aba2f141b6313e441 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    64 schema:name Clinical Trials, Phase III as Topic
    65 rdf:type schema:DefinedTerm
    66 N089810538743418d9bca085526770e41 rdf:first sg:person.0630643206.07
    67 rdf:rest N7545a8896c9d443bb9e8e70c3345194c
    68 N10cf43f66b054561bfd3ff3675205855 schema:name Springer Nature - SN SciGraph project
    69 rdf:type schema:Organization
    70 N17281161b3ea411698484893e9e53fa4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    71 schema:name Half-Life
    72 rdf:type schema:DefinedTerm
    73 N17bd77daadac4de48ff4c8a134c65653 rdf:first sg:person.0646360451.54
    74 rdf:rest N97b8b4aaeca248eebcd31ede27af6500
    75 N279339dfb7b54e1da28521ef6ffa79f5 schema:volumeNumber 34
    76 rdf:type schema:PublicationVolume
    77 N28528d82a61949db9f99e1bac0785a63 schema:issueNumber 2
    78 rdf:type schema:PublicationIssue
    79 N29030e6d354e4107afa289902fce22f7 schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    80 schema:familyName Wu
    81 schema:givenName Dianna
    82 rdf:type schema:Person
    83 N2d78714f50a7455f859d2957d9ea05f2 rdf:first Nd39a8dfa415b4b00a993719b70e630fa
    84 rdf:rest N089810538743418d9bca085526770e41
    85 N330b940d6d1b4dac931d8cc579dfe6a4 rdf:first sg:person.01336302136.32
    86 rdf:rest N5a8cd998680d4732a6b8fe73d36596c0
    87 N33fabb5798f14548b002bd3d47a515c9 schema:name readcube_id
    88 schema:value ef9bc3a1091751c77f1ed53a199e732255a92367ec320256281417411c56aa02
    89 rdf:type schema:PropertyValue
    90 N37a1749551ea465caa9284a8d599b889 rdf:first sg:person.0775237636.64
    91 rdf:rest Ne356668d49c743cbb91e5d6cf7931fdb
    92 N43a071330379414dac6deb1bc6eaa021 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    93 schema:name Antibodies
    94 rdf:type schema:DefinedTerm
    95 N445766713850494c95b5d942a11ed7fd schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    96 schema:familyName Zhou
    97 schema:givenName Zexun
    98 rdf:type schema:Person
    99 N51bb90272f2a4e419173629d937c8e28 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    100 schema:name Abatacept
    101 rdf:type schema:DefinedTerm
    102 N5a8cd998680d4732a6b8fe73d36596c0 rdf:first N73f60f4f7c5446899a8b5f5eda2fc034
    103 rdf:rest Nb21146332ee046f8a8f4fe2094108dbb
    104 N63db32fd56434c80a85895f256e71868 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    105 schema:name Immunoconjugates
    106 rdf:type schema:DefinedTerm
    107 N6437f89cb86b41c2888c93d7a3723d3c rdf:first sg:person.01111466236.19
    108 rdf:rest Ne28576d7b11c48fabf89ca62a8518af8
    109 N73f60f4f7c5446899a8b5f5eda2fc034 schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    110 schema:familyName Shen
    111 schema:givenName Yun
    112 rdf:type schema:Person
    113 N7545a8896c9d443bb9e8e70c3345194c rdf:first sg:person.014363567577.38
    114 rdf:rest rdf:nil
    115 N92594c8c03d9455cb74cfb6828d52b13 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    116 schema:name Area Under Curve
    117 rdf:type schema:DefinedTerm
    118 N957a909c3e48463e9c74e0b7b2734997 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    119 schema:name Clinical Trials, Phase II as Topic
    120 rdf:type schema:DefinedTerm
    121 N97b8b4aaeca248eebcd31ede27af6500 rdf:first sg:person.01166761064.07
    122 rdf:rest N330b940d6d1b4dac931d8cc579dfe6a4
    123 N9b2b2080408e435da502e48dbd469dee schema:name doi
    124 schema:value 10.1007/s40261-013-0153-2
    125 rdf:type schema:PropertyValue
    126 N9d1aec74ad924109a8f28b837abbb778 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    127 schema:name B7-2 Antigen
    128 rdf:type schema:DefinedTerm
    129 Na59476fa1ca64764a637d39a8852ecbe schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    130 schema:familyName Zhan
    131 schema:givenName Ping
    132 rdf:type schema:Person
    133 Nb21146332ee046f8a8f4fe2094108dbb rdf:first Na59476fa1ca64764a637d39a8852ecbe
    134 rdf:rest Nc834438601964111b44fbbf40714b0b6
    135 Nb7e2ac01c61548c485e00ace7756caa8 schema:name dimensions_id
    136 schema:value pub.1050298806
    137 rdf:type schema:PropertyValue
    138 Nb9467871d97841769433b7de866dca49 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    139 schema:name Humans
    140 rdf:type schema:DefinedTerm
    141 Nba28c3ed7ded4d97a077d29032a15dfc schema:name nlm_unique_id
    142 schema:value 9504817
    143 rdf:type schema:PropertyValue
    144 Nc834438601964111b44fbbf40714b0b6 rdf:first N445766713850494c95b5d942a11ed7fd
    145 rdf:rest N37a1749551ea465caa9284a8d599b889
    146 Nce7c8c54400b479781378e65cd9ddc2d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    147 schema:name Adult
    148 rdf:type schema:DefinedTerm
    149 Nd05ad56666e0456c8bb1cc93424d1457 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    150 schema:name Immunosuppressive Agents
    151 rdf:type schema:DefinedTerm
    152 Nd137d44b78b44dedaaf8135644b139e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    153 schema:name Kidney Transplantation
    154 rdf:type schema:DefinedTerm
    155 Nd39a8dfa415b4b00a993719b70e630fa schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    156 schema:familyName Proszynski
    157 schema:givenName Elizabeth
    158 rdf:type schema:Person
    159 Ne28576d7b11c48fabf89ca62a8518af8 rdf:first sg:person.01157601436.77
    160 rdf:rest N2d78714f50a7455f859d2957d9ea05f2
    161 Ne356668d49c743cbb91e5d6cf7931fdb rdf:first N29030e6d354e4107afa289902fce22f7
    162 rdf:rest N6437f89cb86b41c2888c93d7a3723d3c
    163 Ne4200569f18b49b89f2f3ecb3a6c615f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    164 schema:name Dose-Response Relationship, Drug
    165 rdf:type schema:DefinedTerm
    166 Ne4d5082815cd4b38a6c0053639dafa1e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    167 schema:name Time Factors
    168 rdf:type schema:DefinedTerm
    169 Nfddc6d8555194374b13de69132ae793b schema:name pubmed_id
    170 schema:value 24217983
    171 rdf:type schema:PropertyValue
    172 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    173 schema:name Medical and Health Sciences
    174 rdf:type schema:DefinedTerm
    175 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    176 schema:name Clinical Sciences
    177 rdf:type schema:DefinedTerm
    178 sg:journal.1100199 schema:issn 1173-2563
    179 1179-1918
    180 schema:name Clinical Drug Investigation
    181 rdf:type schema:Periodical
    182 sg:person.01111466236.19 schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    183 schema:familyName McGirr
    184 schema:givenName Nadia
    185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111466236.19
    186 rdf:type schema:Person
    187 sg:person.01157601436.77 schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    188 schema:familyName Soucek
    189 schema:givenName Kathleen
    190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157601436.77
    191 rdf:type schema:Person
    192 sg:person.01166761064.07 schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    193 schema:familyName Townsend
    194 schema:givenName Robert
    195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166761064.07
    196 rdf:type schema:Person
    197 sg:person.01336302136.32 schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    198 schema:familyName You
    199 schema:givenName Xiaoli
    200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336302136.32
    201 rdf:type schema:Person
    202 sg:person.014363567577.38 schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    203 schema:familyName Masson
    204 schema:givenName Eric
    205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014363567577.38
    206 rdf:type schema:Person
    207 sg:person.0630643206.07 schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    208 schema:familyName Pursley
    209 schema:givenName Janice
    210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630643206.07
    211 rdf:type schema:Person
    212 sg:person.0646360451.54 schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    213 schema:familyName Shen
    214 schema:givenName Jinshan
    215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646360451.54
    216 rdf:type schema:Person
    217 sg:person.0775237636.64 schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    218 schema:familyName Geng
    219 schema:givenName Dong
    220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775237636.64
    221 rdf:type schema:Person
    222 sg:pub.10.1038/clpt.2010.331 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026754692
    223 https://doi.org/10.1038/clpt.2010.331
    224 rdf:type schema:CreativeWork
    225 sg:pub.10.1038/clpt.2012.84 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020898645
    226 https://doi.org/10.1038/clpt.2012.84
    227 rdf:type schema:CreativeWork
    228 sg:pub.10.2165/11316480-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025688462
    229 https://doi.org/10.2165/11316480-000000000-00000
    230 rdf:type schema:CreativeWork
    231 sg:pub.10.2165/11319980-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022781285
    232 https://doi.org/10.2165/11319980-000000000-00000
    233 rdf:type schema:CreativeWork
    234 https://doi.org/10.1056/nejmoa050085 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052307919
    235 rdf:type schema:CreativeWork
    236 https://doi.org/10.1056/nejmra033540 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041854653
    237 rdf:type schema:CreativeWork
    238 https://doi.org/10.1097/tp.0b013e31819b5a58 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017865661
    239 rdf:type schema:CreativeWork
    240 https://doi.org/10.1097/tp.0b013e3181ff87cd schema:sameAs https://app.dimensions.ai/details/publication/pub.1012888147
    241 rdf:type schema:CreativeWork
    242 https://doi.org/10.1097/tp.0b013e3182007b95 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009438606
    243 rdf:type schema:CreativeWork
    244 https://doi.org/10.1111/j.1600-6143.2004.00332.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1008106653
    245 rdf:type schema:CreativeWork
    246 https://doi.org/10.1111/j.1600-6143.2005.00749.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1005387107
    247 rdf:type schema:CreativeWork
    248 https://doi.org/10.1111/j.1600-6143.2009.03005.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1051343043
    249 rdf:type schema:CreativeWork
    250 https://doi.org/10.1111/j.1600-6143.2010.03016.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1023223598
    251 rdf:type schema:CreativeWork
    252 https://doi.org/10.1111/j.1600-6143.2010.03338.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1035491415
    253 rdf:type schema:CreativeWork
    254 https://doi.org/10.1177/0091270007306958 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031261826
    255 rdf:type schema:CreativeWork
    256 https://doi.org/10.1371/journal.pone.0026459 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016973491
    257 rdf:type schema:CreativeWork
    258 https://doi.org/10.1681/asn.2009111109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012075613
    259 rdf:type schema:CreativeWork
    260 https://doi.org/10.2215/cjn.03791106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031418032
    261 rdf:type schema:CreativeWork
    262 https://doi.org/10.4155/bio.10.54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052956253
    263 rdf:type schema:CreativeWork
    264 https://doi.org/10.4155/bio.12.79 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053687013
    265 rdf:type schema:CreativeWork
    266 https://www.grid.ac/institutes/grid.419971.3 schema:alternateName Bristol-Myers Squibb (United States)
    267 schema:name Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA
    268 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...